This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Dr. Katharine (Katie) Duncan, PhD
Director, CMC Policy and Advocacy at GlaxoSmithKline (GSK)
Speaker

Profile

Katharine (Katie) Duncan is a Director of CMC Policy and Advocacy with Global Regulatory Affairs/CMC Excellence. Prior to joining GSK, Katie was a senior pharmaceutical quality assessor with the Office of Pharmaceutical Quality at the US Food and Drug Administration. She previously worked in small molecule drug discovery at a biotechnology company in San Diego, CA. She received her Ph.D. in organic chemistry from the Scripps Research Institute in La Jolla, CA and B.A. from Amherst College in Amherst, Massachusetts.

Agenda Sessions

  • Enzymatic Approaches to Oligonucleotide Manufacture

    5:15pm
  • Regulatory Expectations for Synthetic Oligonucleotides: Trends, Challenges, and Opportunities

    2:00pm